Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...
ScienceAlert on MSN6h
FDA-Approved Nasal Spray For Depression Is First Of Its KindA ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...
Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...
On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...
The roots of the various conditions defined by the medical field of psychiatry—such as major depression, schizophrenia, or generalized anxiety disorder—are still not well understood.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback